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Abstract 
       Due to various biological factors, males and 
females differ in their response to drug treatment. 
However, there is still a lack of knowledge of the effects 
resulting from sex-differences in the medical field, 
primarily due to females' underrepresentation in 
clinical studies. Considering severe diseases related to 
the cardiovascular system, which are likely to be 
perilous, counteracting this lack and emphasizing the 
need for sex-dependent drug treatment is of high 
importance. Thus, this research-in-progress paper aims 
to strengthen the female perspective in drug 
management by proposing design considerations on IS 
regarding recommender systems in healthcare to 
reinforce shared decision-making and person-centered 
care. The resulting artifact presented will be a reference 
architecture with a mobile application as the interface 
to patients and healthcare professionals as well as a 
data-driven backend to collect and process data on sex 
specificity in the medical treatment of cardiovascular 
diseases (CVD). 
 
1. Introduction  
 
Despite the increasing awareness that sex-related 
differences between males and females need to be 
considered in drug treatment (e.g., [1], [2]), there is a 
persisting lack of knowledge on varying drug tolerance 
based on the sex of the patient, especially for females 
(e.g., [3][4]). Biological differences between males and 
females lead to differences in the pharmacokinetics and 
the pharmacodynamics, in the drug absorption, in the 
drug distribution in tissues, in the metabolism or the 
differing excretion via the kidney and intestine [3]. The 
biological causes for these differences lie predominantly 
in the unequal genetic constitution of males and females, 
diverse body conditions - e.g., females tend to have a 
lower body mass index, a smaller size of organs and 
more adipose tissue - and in the impact of sexual 
hormones [5][3]. Additionally, several studies showed 
that the adverse side effects of medical drug use are 
more frequent for females than males [1]. Thus, there is 
an obvious need for sex-dependent drug treatment. 
However, females are still underrepresented in clinical 
trials. Even in the field of animal testing drugs are 
predominantly tested on male animals assuming that sex 
differences play no role in the clinical effect [3]. In this 
regard, Karlsson-Lind et al. (2017) show that 
information on sex differences lacks for a variety of 
available medications [1]. Also, Regitz-Zagrosek 
(2004) depicts that males and females differ in their 
willingness to participate in their treatment process 
actively and women tend to take different amounts of 
possibly interacting over-the-counter drugs for self-
medication in addition to prescribed drugs [3]. 
Especially for severe diseases such as CVDs, which 
are the most relevant cause of mortality and morbidity 
worldwide, sex-related cardiovascular risk-factors and 
respective drug administration are essential 
determinants of treatment success [5]. However, there is 
a lack of knowledge for female-specific needs in 
medical treatment, which accordingly can become 
extremely dangerous [6].  
All those factors emphasize the importance of 
gaining fundamental knowledge on female-specific 
needs in drug management, especially in CVD. Thus, 
our study proposes design consideration for information 
systems (IS) focusing on strengthening the female 
perspective in drug administration, regarding aspects 
such as female-specific side-effects and drug dosage and 
potential drug interactions. Specifically, the focus is on 
the decision-making process for the medical treatment 
of CVD patients. With this, we aim to contribute design 
knowledge on how to identify, communicate, and 
handle female-specific CVD drug responses. While 
female patients are our primary stakeholders, healthcare 
professionals need to be considered and are the primary 





decision-makers in medical treatment. Also, as the sex 
inequity in medical treatment arises from narrow 
research, both from academia and the drug industry, 
they are essential stakeholders to close the persisting 
knowledge gap on sex-specificities in medical 
treatment. Our study focuses on Germany as a target 
country. 
The paper is structured as follows: First, we 
introduce core socio-technical and technical 
foundations. Second, we review the literature to carve 
out the knowledge gap and gain insights into the 
solution space. Third, we introduce our general design 
science research methodology. Fourth, we describe the 
first iteration of our proposed IS artifact and the first 
evaluation cycle through a quantitative survey. Last, we 
discuss our results and limitations as well as introduce 
the further course of our study. 
  
2. Theoretical background 
 
2.1 Personalized healthcare 
 
Tailoring services towards the individual is an 
essential element of healthcare delivery [7]. Various 
concepts address how to do this, such as personalized 
medicine, person-centered care, and shared decision-
making. Personalized medicine “encompasses the 
application of genomic and molecular data to target 
better the delivery of healthcare and more holistic 
lifelong approaches.” [8, p. 208]. However, Di Paolo et 
al. (2017) discovered that most personalized medicine 
literature focuses on tailoring treatments to patients’ 
diseases without considering patients’ needs, beliefs, 
behavior, values, wishes, utilities, environment, and 
circumstances [7]. Patient preferences were hardly 
considered when evaluating new medicines rather than 
focusing on the stratification according to individual 
biological information. As a response to that, person-
centered care focuses on the person as a whole and is 
responsive towards the person’s individual needs and 
preferences [9]. To achieve person-centered care, 
mutual involvement, and collaboration of the healthcare 
professional with the patient are required [10]. This 
collaboration process is referred to as shared decision-
making. Shared decision-making is “an approach where 
clinicians and patients share the best available evidence 
when faced with the task of making decisions, and 
where patients are supported to consider options, to 




2.2 Explainable recommender systems in 
healthcare 
 
Recommender systems are tools to provide users 
with suggestions for action [11]. With the digitalization 
in almost all areas of daily life and the resulting increase 
in data volume and complexity, these systems assist 
users in dealing with this through condensing relevant 
information to generated recommendations. This is also 
evident in the healthcare industry [12]. To develop 
recommender systems, three different techniques are 
typically used [11]. 
(1) Collaborative filtering is the process of clustering 
people with similar usage profiles. Likewise, this 
approach can be applied across similar application areas 
[13]. (2) Knowledge-based filtering uses existing 
knowledge about the user, such as demographics [11]. 
(3) Content-based filtering compares different products 
that the user has already used to estimate their similarity 
and propose new products accordingly [14]. 
Nevertheless, the implementation of only one of these 
solutions can lead to the so-called "cold start problem". 
Due to an information gap, the recommender system 
cannot develop a precise recommendation [15]. 
Therefore, the use of hybrid recommender systems is a 
frequently used approach. Within these systems, at least 
two decision strategies are combined to identify 
recommendations [16]. 
To process a large amount of data through the 
recommender system, various artificial intelligence (AI) 
methods are used in healthcare today [13]. These 
approaches mostly suggest a recommendation similar to 
collaborative filtering but in a more precise manner [17]. 
AI refers, besides others, to the concept of machine 
learning (ML) and deep learning (DL). These models 
are trained in a data-driven way using mathematical 
procedures without explicit programming [18].  
Simultaneously, several problems are associated 
with these AI-methods. One main problem is the 
complexity of the generated models resulting in black-
box models [19]. This black box model is not traceable 
and, therefore, leads to trust issues. Consequently, this 
lack of trust reduces the acceptance and willingness to 
use such a recommender system [20]. The explainable 
AI (XAI) research field attempts to address this issue 
while preserving AI's benefits [21]. As trust is a core 
element in healthcare, explainability is a frequently 
targeted goal for AI systems in healthcare research [22]. 
 
3. Methodology  
 
Our study aims to support women diagnosed with 
CVD in their medical treatment decision-making 
process. Specifically, this study reports on a first 
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iteration of the problem-centered approach to the Design 
Science Research Methodology proposed by Peffers et 
al. (2007) [23]. Further iterations will follow in 
subsequent studies. 
Identify problems & define objectives. We started 
the first design cycle by investigating sex differences in 
medical treatment and the under-representation of 
females in clinical trials. Hereby, we regarded the needs 
of female patients as well as the demands of healthcare 
professionals within the treatment decision-making 
process (e.g., [1], [24]). For this, relevant concepts were 
identified to shape the solution space: For socio-
technical challenges faced through sex differences in 
medical treatment, the concepts of shared decision-
making (e.g., [10]) and person-centered care (e.g., [25], 
[26]) were identified. For the technical perspective on 
supporting shared-decision-making and person-
centered care, explainable hybrid recommender systems 
(e.g., [13], [27]) were chosen as a foundation.  
Relevant literature is consulted and condensed to a 
precise research gap and core findings to be considered 
in the solution space based on a structured literature 
review following the approach of Webster and Watson 
(2002) [28]. We aim to find extant contributions dealing 
with recommender systems in healthcare for shared 
decision-making. We analyze the databases PubMed, 
ScienceDirect, and Web of Science to find healthcare-
related contributions. Regarding technical 
contributions, we examine ACM Digital Library and 
IEEE Xplore. For the field of business information 
systems, AIS eLibrary is consulted. The following 
search term pseudocode is used: 
((health care | care) AND (shared decision-making | 
patient-cent* | person-cent*) AND (gender equity | 
gender disparity | gender differences | gender bias) 
AND (recommend* system | decision support system) 
AND (explainab* recommend* | artificial intelligence | 
machine learning | deep learning | XAI)) 
Thereby, we were able to identify 5454 
contributions. Through a meta-analysis, full-text 
analysis as well as a forward and backward search, we 
classify 46 contributions as relevant. The results are 
presented in Chapter 4. 
Design and development. To tackle sex differences 
in medical treatment, this study proposes a reference 
architecture as an artifact to support females in their 
medical treatment decisions. Specifically, the identified 
core concepts are used as a basis for a set of design 
decisions regarding the required functionality of such an 
artifact. These socio-technical design decisions are then 
transferred into a set of technical design decisions 
prescribing a possible implementation for the targeted 
artifact. This reference architecture serves as a 
foundation for implementing such an artifact in the 
specific context of females with CVD sickness. The 
results are presented in Chapter 5.  
Evaluation. In this first iteration of the design cycle, 
we evaluate the relevance of the problem space and the 
basic idea of the reference architecture to generate data-
driven female-specific recommendations on medical 
treatment. The evaluation is conducted as a quantitative 
survey with 43 German females at 35 years of age or 
older, presented in Chapter 6. 
Communication. In this first design cycle, we 
propose a reference architecture as an artifact rooted in 
extant research. The artifact can be considered an 
exaptation contribution [29] as it tackles a new problem 
with established concepts and solutions. With this first 
iteration of the design cycle, we posit a research-in-
progress paper that will eventually yield a nascent 
design theory contributing design knowledge to general 
healthcare IS and sex-sensitive IS. Future research will 
build on these initial steps.  
 
4. Literature review 
 
The literature review aims to find extant 
contributions dealing with recommender systems in 
healthcare for shared decision-making to understand the 
targeted gap better and identify reusable concepts.  
Person-centered care and sex differences. Person-
centered care benefits both the patient, e.g., through 
enhanced knowledge, improved relationship with 
providers, service experience and satisfaction, treatment 
compliance and health outcomes, as well as the health 
system, e.g., through cost-effective service delivery 
[30]. Nevertheless, many patients, especially females, 
do not experience person-centered care due to a lack of 
insight into operationalizing person-centered care for 
females [31]. One explanation is the lack of attention 
paid to person-centered care in medical guidelines [30]. 
Multiple strategies are proposed to improve person-
centered care for females, including patient-oriented 
tools in guidelines. These tools can, for example, 
include information about the condition, lifestyle 
advice, psychological strategies, and strategies for 
communicating with healthcare professionals.  
An observational study by Meijers (2019) showed 
that the application of shared decision-making in 
practice increased between 2007 and 2015 [32]. Despite 
this increase, the level of shared decision-making is still 
limited and leaves room for improvement. Another 
study using the same measurement instrument in cardiac 
stress testing found no significant sex effect [33].  
A system allowing patients to access their medical 
records maintained by a healthcare facility supports 
patients to have an active role in their care process [34]. 
Ideally, this system also allows patients to interact with 
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their healthcare providers. Currently, the management 
of chronic conditions often relies on face-to-face visits 
and infrequent measurements [35]. This may cause a 
delay when interventions are needed since patients tend 
to wait until symptoms are acute. Late detection of 
serious symptoms can lead to expensive healthcare 
services, requiring hospitalization, emergency room 
visits, and unplanned readmissions. Early detection of 
deteriorating health is therefore needed to improve 
health outcomes and manage healthcare costs. Mobile 
health has shown to impact health-related behaviors, 
allowing patient self-management of their health status. 
An example of a mobile health app monitoring and 
analyzing health data of persons with and without 
chronic diseases, and automatically alerting care 
support staff based on purpose-developed algorithms is 
the one developed in the study by Petersen (2019). The 
app has three functional areas: health data, personal 
profile, and secure messaging. The health data was 
recorded through a fitness tracker smartwatch and data 
entered by the patients manually. The personal profile 
involved information on the patient’s personal 
preferences, health goals, and social data. This 
information is useful for healthcare providers to deliver 
person-centered care. Secure messaging was possible 
24/7 with a healthcare professional. The pilot 
demonstrated that persons with chronic conditions were 
actively engaged for a longer time than persons without 
chronic diseases. Besides, the pilot uncovered 
substantial potentials for the reduction in care costs for 
persons with chronic care conditions.  
Recommender systems. The necessity of 
recommender systems in healthcare is frequently 
discussed in research. Contributions such as [36] 
highlight the need to integrate shared decision-making 
with interactive recommender systems as the most 
appropriate way to raise patient awareness. Therefore, 
their application can be found in various approaches 
such as telehealth [37], chatbots [36], or mobile 
applications [41]. These approaches are also used to 
address different areas of healthcare, such as diets [38], 
drug treatment [39], dementia [40], support for the 
elderly [41], or chronic diseases [42]. The described 
recommender systems mostly use a hybrid collaborative 
filtering technique to overcome the cold start problem 
[42]. According to these contributions, mobile 
applications differentiate themselves from others by 
their high flexibility and acceptance, enabling the 
elicitation of sensor and fitness data as an additional 
source of information [43].  
Furthermore, the review also shows that until 2017, 
different cluster algorithms were mainly used for the 
prediction of recommender systems. Due to the high 
computational complexity, these contributions also 
introduce outsourcing to cloud services [44]. On the 
other hand, recent contributions focus on more complex 
algorithms such as DL or natural language processing 
due to their high predictive power and are also used in 
high-stakes areas like radiology. Therefore, those 
recommendations can support physicians in the drafting 
of reports [45]. Simultaneously, the examination of 
recent studies in this field reveals the necessity of 
traceability of the predictions. Especially in critical 
areas such as cancer detection [36]. Even in the 
preliminary contributions, this has already been 
discussed by pointing out decision factors of neural 
networks when recommending treatments [46].  
Identified knowledge gap. The analysis proves the 
necessity of paying attention to how to improve sex 
equity and shared decision-making in medical practice. 
Several strategies and solutions were highlighted. An 
already established approach is the use of recommender 
systems through the application of mHealth, based on 
explainable AI. However, in the analysis, no 
contributions could be identified dealing with the 
development of IS for shared decision-making to tackle 
the prevailing sex differences despite the frequently 
discussed relevance of this gap [31]. Therefore, our 
study aims to develop a reference architecture to support 
further developments in this field. 
 
5. Designing female-sensitive personalized 
drug management 
 
       In this section, we propose a set of means-end 
relations, i.e., appropriate means (M) to achieve ends 
(E) associated with the problem domain [47]. Those are 
derived from both technical and socio-technical cause-
effect relations identified from the reviewed literature 
and inferred from the core concepts. These means-end 
relations guide not only the instantiation of the derived 
reference architecture, shown in Fig. 1, in our specific 
context but can also be reused for health-related IS in 
general.  
 
5.1. First design cycle 
 
Socio-technical considerations. Our approach to 
tackling the knowledge gap on sex differences in 
medical treatment evolves around increased patient 
participation. Therefore, the artifact must be designed to 
facilitate ease of use as a determinant for increased 
patient participation (e.g., [48]) (E1). Following our 
objective to develop an application that allows for 
female-centered care, as a specific manifestation of 
person-centered care, the literature emphasizes that it is 
vital to elicit and incorporate an individual's values and 
preferences (e.g., [25]). Therefore, the artifact has to 
provide a way to collect and store data about patient 
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preferences (E2). With the aim of the artifact to enable 
a shared decision-making process, the literature points 
out the importance of sharing the best available 
evidence when facing the task of making a decision 
(e.g., [10]). Therefore, the artifact has to provide ways 
to track different types of information, including person-
centered data, user preferences, and data on overall 
patient wellbeing, general healthcare-related data, and 
female-specific healthcare-related data (E3).  
To deliver ground for a justified discussion to yield 
shared decision-making for medical treatment (e.g., 
[49]), the artifact has to provide a condensed account of 
the input data (E4). This information has to be shared 
with the patient to trigger shared decision-making and 
the healthcare professionals as a common ground for 
discussion [10] (E5). However, they require different 
degrees of information. While healthcare professionals 
need detailed explanation and reasoning, for example, 
about drug interactions, patients may rather be 
interested in whether and how their preferences can be 
mapped to their treatment (e.g., [49]). Hence, the artifact 
must display information with varying perspectives and 
degrees of detail per stakeholder (E6). Lastly, the 
general problem targeted by the artifact arises from the 
shortage of female-specific health-related data. 
Therefore, the artifact also shares the female-specific 
data collected by the artifact with academic and industry 
drug research (E7) to close the knowledge gap for sex 
differences in medical treatment.  
Technical considerations. To increase patient 
participation, the artifact needs to be flexibly available 
to the patient anywhere, at any time [48]. Therefore, a 
mobile application was chosen as the appropriate 
interface for the patients (M1a). Moreover, ease of use 
is facilitated through functionalities, such as taking a 
picture of a medication instead of an interface requiring 
long and tiring inputs by the user [50] (M1b).  
User preferences can be elicited by incorporating a 
patient survey. For the design of the survey, we follow 
extant work (e.g., [51]) (M2). To achieve M2, extant 
solutions incorporate various types of data. First, 
general healthcare-related data can contribute to the 
overall understanding of the interplay of drugs, 
symptoms, and side effects, either specific for CVD or 
general and either female-specific or sex-independent 
data as proposed by the literature stream on evidence-
based medicine (e.g., [52]). This data can be made 
available to the artifact by establishing links to 
renowned healthcare-related databases, such as  
PharmacoGenomic Mutation Database (PGMD) [53] 
and the Medscape Interaction Checker [54]. Therefore, 
the artifact must provide linkages to healthcare-related 
databases (M3a). Second, extant solutions elicit person-
centered data directly related to the sickness, such as 
monitoring drug intakes and data about the general well-
Figure 1. Reference architecture for female-sensitive drug management. 
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being. Extant research frequently refers to this as 
‘patient profiling’, including any information about 
activities and the progression of symptoms and side-
effects over time (e.g., [55]). Therefore, the artifact 
needs to provide users functionality to enter and track 
all data related to their patient profile (M3b). Moreover, 
Gyrard et al. (2020) propose to enhance patient-centered 
data with sensor data such as heart rates [13]. While this 
is not in the scope of our artifact, it may be available in 
other health-related applications. Other wellbeing and 
health-related applications, such as Apple Health or 
menstrual cycle calendars, may also collect insightful 
information and can deliver it to the artifact’s 
recommendation engine if appropriately connected 
(e.g., [56], [52]). Therefore, the artifact should provide 
touchpoints to connect other health- and wellbeing-
related applications via APIs to retrieve further relevant 
data (M3c).  
A highly frequented approach to condense 
information in healthcare is to provide 
recommendations based on the observed data within 
recommender systems (e.g., [39], [36]). Therefore, the 
artifact must provide a recommendation engine to 
condense all the observed data for the shared decision-
making process (M4a). Initial recommender systems 
primarily rely on one type of data (e.g., 
transaction/behavioral data) and use the collaborative 
filtering method [57]. More advanced recommender 
systems additionally incorporate rather static data, such 
as preference profiles (e.g., [58], [59], [60]). For the 
artifact at hand, the recommender system ought to 
incorporate all the available data. Extant solutions 
exemplify how to incorporate user preferences [12], 
patient profiles (e.g., [55]), and external database (e.g., 
[52]). Therefore, the artifact should be designed as a 
hybrid recommender system to incorporate 
transactional data and user preferences (M4b). For 
recommender systems, their applications range from 
disease discovery [67] over suggestions for physical 
activity [60] to actual therapeutic recommendations 
[57], i.e., many types of recommendations are possible.  
As a starting point, the artifact will provide 
recommendations on drug interactions, preference-
based alternations of drug intakes, and for scheduling an 
appointment with a healthcare professional in the case 
of irregularities (M4c). For any of these 
recommendations and any of the posited data sources, 
both female- and patient-specific as well as general 
health-related data, any recommender system faces the 
‘cold start problem’ (e.g., [27], [16]). The hybrid 
approach allows us to propose initial recommendations 
based on a limited amount of data and then collect and 
learn from data accrued over time. Accordingly, initial 
recommendations may rely on sex-independent data and 
as the database grows over time, recommendations can 
become more tailored to female- and patient-specific 
needs. Also, with the database growing over time, more 
types of recommendations may be possible. A value can 
be created with a large and continuously growing 
database through so-called data network effects, where 
the multi-sided exchange among individual users allows 
to improve recommendations for each user [61]. 
Therefore, the artifact should stimulate the continuous 
collection and recording of data to evolve the 
recommendations continuously (M4d).  
To achieve shared decision-making, the patient, who 
is in full possession of the mobile application and the 
data therein, can share information with the healthcare 
professional. Therefore, a login for healthcare 
professionals is provided in the artifact, where the 
patient can choose to share data explicitly with the 
healthcare professional (e.g., through using a QR code 
mechanism), so that the data remains secure (e.g., [37]) 
(M5). Recommendations require an explanation to be 
understood and followed by healthcare professionals 
and patients. Therefore, explainability is a core issue for 
any recommendation system in the healthcare context 
[22]. This issue is, for example, addressed by Che et al., 
2015, who explain their DL-based mortality prediction 
[62]. Therefore, the artifact must provide sufficient 
explanations for each recommendation (M6a). 
Explanations must be adapted to stakeholders [63]. At 
the same time, a patient may be satisfied with a 
recommendation and indicators for how their 
preferences were considered and will be realized by a 
recommendation, a healthcare professional demands 
further details such as the specific interplay of 
components of drugs. Therefore, the artifact must 
provide different perspectives and granularities of 
explanations for each recommendation (M6b).  
Lastly, the artifact wants to contribute the collected 
data such as female-specific symptoms, side-effects, 
sickness progressions, to the drug research, both 
academic and industry, to close the gap of sex-
differences in CVD treatment. Both storing and sharing 
health-related data raises data security issues, which 
must be addressed for the IS artefact to be viable. 
Therefore, the artifact provides an API to retrieve fully 
anonymized datasets from the backend (M7).  
 
5.2. First evaluation cycle 
 
In design science research, an evaluation is crucial 
to demonstrate the utility, quality, and efficacy of a 
proposed artifact [64]. While the designed reference 
architecture followed socio-technical requirements and 
was technically grounded on findings in extant research, 
we evaluate and plan to evaluate further both the 
relevance of the problem space as well as the suitability 
of the proposed solution. In this first evaluation cycle, 
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we conducted a quantitative survey to verify the 
relevance of lacking sex-specific knowledge to females 
and whether females would like to be empowered 
through technology to better participate in their medical 
treatment decision-making process.  
Method. A quantitative online survey was 
conducted from 19th to Jun. 25th, 20201. A pretest was 
conducted to check for clarity and correct spelling of the 
questions. The participants were reached via a recruiting 
pool, receiving incentives, as well as by using snowball 
sampling. Women of 35 years of age or higher were 
included in this German study. We applied a 5-point 
Likert scale (1 = strongly disagree, 5 = strongly agree). 
In total, 45 participants completed the survey, from 
which two low-effort responses were excluded from the 
analysis due to non-varying scale options; therefore, the 
sample group consists of 43 completed surveys.  
Procedure. The survey opened with an introduction, 
addressing the lack of knowledge on sex differences in 
medical treatment. Along with eight questions, 
respondents were asked for their interest in receiving 
medical recommendations and their willingness to track 
their medical condition, share their data for 
recommendation processing, and forward personal 
health data to healthcare professionals and drug 
research. Also, their current use of health-related 
applications was inquired.  
Results. Eighty-four percent of the respondents 
strongly agreed to wish to receive recommendations 
regarding drug interactions, preference-based 
alternations of drug intakes, and - in case of 
irregularities - to get in touch with a healthcare 
professional (M = 4.76, SD = 0.55). This is in line with 
previous research on technology-enhanced, person-
centered care reporting that patients with chronic 
conditions, such as CVD, are “more likely to remain 
engaged” with the technology [35, p. 10]. Receiving 
explanations in addition to the recommendation itself to 
understand better the effects of one’s drug usage and 
influencing factors was strongly wished for as well      
(M = 4.67, SD = 0.64). Thirty percent neither agreed nor 
disagreed with preferring a mobile application to collect 
and store personal health data, preferences, disease-
specific data, and data on one’s overall well-being; 
25.6% agreed (M = 3.00, SD = 1.24). Regarding data 
sharing with healthcare professionals, 25.6% agreed and 
44.2% strongly agreed (M = 3.93, SD = 1.23). Sharing 
the data with academic and industrial research, was 
37.2% agreed on and 30.2% strongly agreed on by 
participants (M = 3.16, SD = 1.20). However, 
participants would rather not share their data with the 
recommender system for the sake of receiving more 
precise drug recommendations or - in equal shares - are 
 
1 See https://doi.org/10.13140/RG.2.2.27950.54086 
regardless of that (30.2% each, M = 2.65, SD = 1.27). 
More than half of the participants already use a fitness 
app to track activities such as running or biking (55.8%). 
A calendar app for the menstrual cycle is used by 23.3%. 
The general perception of the respondents that sharing 
personal health-related data can help overcome the lack 
of sex equity in medical research was consensual (M = 
3.44, SD = 1.06). 
Implications. The survey showed that respondents 
are willing to receive recommendations regarding their 
drug management. They also demand explanations for 
the provided recommendations and are willing to use the 
information for engaging in shared decision-making 
with their healthcare professionals. Also, they are 
willing to give away their data for research purposes to 
enhance female-specific medical treatment. However, 
in contrast to the high motivation to participate in shared 
decision-making for their medical treatment, they are 
reluctant to receiving improved recommendations to 
compensate for their data sharing. This implies that the 
adoption of such technology and, thus, the data 
collection, are more likely to succeed if users benefit 
from using the app through concomitant outcomes, i.e., 
tracking their health-record and getting detailed 
explanations on the observable data. Also, respondents 
do not explicitly consider a mobile application the 
preferred option to collect their health-related data. 
However, this is contrary to the result that more than 
half of the participants already use health-related mobile 
applications. In sum, the study shows that there is a need 
for female-sensitive, personalized recommendations 
and explanations for which data-driven solutions with 
female-specific design considerations are a promising 
path. Further research on socio-technical requirements 
is required to understand better female patient’s needs 
as well as the utility of such applications in the daily 
routines of women to deduct specific sex-related 
requirements for the design of the proposed artefact. 
 
6. Discussion  
 
In this research-in-progress paper, we investigated 
design considerations for technology-enhanced female-
sensitive decision-making regarding CVD's medical 
treatment. The result is a reference architecture with a 
mobile application as the interface to patients and 
healthcare professionals as well as a data-driven 
backend to collect and process data on sex differences 






6.1 Contributions to theory and practice 
 
From a theoretical perspective, there is a lack of 
knowledge on handling sex inequity in healthcare 
occurring through the underrepresentation of females in 
clinical trials. Our study aims to close this gap in three 
ways. First, we apply the concept of person-centered 
care with the aim of closely monitoring the body 
condition of each female patient to make data available 
on female-specific side effects, course of a disease, and 
general wellbeing under medication. Second, we apply 
the concept of shared decision-making to enable females 
to be more involved in their medical treatment decision 
despite the lack of research knowledge on female-
specificity. Third, we apply the technical concept of 
hybrid explainable recommender systems to realize 
female-sensitive drug management along with the 
concepts of person-centered care and shared decision-
making to incorporate sex-differences in medical 
treatment.  
From a practical view, the implementation of the 
reference architecture will serve female patients, 
healthcare professionals, and drug researchers. First, 
female patients are yet frequently not aware of sex 
inequity in clinical trials and what this implies for their 
medical treatment. Based on the mobile application, as 
the patient interface in the reference architecture, female 
patients can better understand how their preferences and 
body specificity can be considered in their medical 
treatment decision. Second, healthcare professionals 
benefit from the condensed data made available to them, 
primarily through the provided explanations, to allow 
them to make better-tailored treatment decisions for 
female patients. Third, the underrepresentation of 
females in clinical trials can be tackled through the rich 
records of female patient data accrued through the 
mobile application. With females accurately tracking 
their health-related data for their personal treatment 
decision, drug research can be pointed towards relevant 
areas of study to facilitate targeted investigation of 
female-specificity in drug research and, ultimately, to 
reduce the gap of female-specific knowledge for 
medical treatments.  
 
6.2 Future research 
 
For the further progression of this study, we plan to 
iterate further design cycles. The evaluation of our 
current research state yielded essential feedback for the 
next design phase. We currently develop and evaluate 
mock-ups as a second design cycle that allows us to get 
intermediate patient feedback between the 
conceptualization and implementation. Having finished 
the conceptualization, the data structure will be derived 
and defined based on relevant data, both from 
underlying drug management data sources and user-
related data, which are integrated into the 
recommendation engine. Subsequently, we plan to 
realize a first implementation of the artifact. Thereby, 
we can build up an essential user base and basic 
functionality such as data collection and 
recommendations based on existing medical interaction 
databases. Hereupon, the user base grows, and more 
female-specific health data becomes available, allowing 
to infer female-specific knowledge.  
Based on these two upcoming design cycles, we seek 
to evaluate further aspects: The architecture feasibility 
will be verified through the actual implementation and 
functional software testing for each component, the user 
interface, and the recommendation engine. The socio-
technical requirements will be evaluated through 
explorative (female) focus groups to identify concrete 
sex-related requirements for the design of the proposed 
artefact to appropriately address the specific needs of 
the target group, the female patients, for a proper 
interaction with the application. The utility of 
recommendations will be assessed through in-app 
feedback and documented changes in patient health-
related data once recommendations were followed. Last, 
the usability of the user interface will be monitored 
based on app usage metrics derived from the user’s 
behavior in the mobile application. 
 
6.3 Limitations  
 
Our study is limited in multiple ways despite the yet 
limited scope of a research in progress paper. First, 
healthcare-related IS underlie strong legal regulations, 
which are mostly country-specific. Therefore, the 
artifact must eventually be aware of its location to 
ensure legal compliance, e.g., regarding data protection 
and privacy regulations in the applicable law. Second, 
as the data collected from patients is intended to be used 
in drug research as a pointer towards relevant areas of 
study, the data collection needs to be safe against any 
type of manipulation. Hence, future research needs to 
target the security aspects of both the mobile application 
as well as the recommendation engine. Third, this 
architecture is limited to German users but is 
prospectively generalizable to other countries, thereby 
extending the user base to benefit from a larger number 
of users for more stable results for the recommender 
system. Fourth, this study is limited to CVD patients. 
However, we posit that architecture can be transferred 
to any sickness affected by female-specific body 
conditions, such as depression and diabetes. Fifth, there 
is still a lack of ready-to-use solutions for explainable 
AI. Accordingly, research is needed to develop 
individual explainable solutions for each specific 
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